Quanterix Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Quanterix Corporation (Nasdaq: QTRX) has successfully completed its public offering of 4,107,142 shares at $70.00 each, securing gross proceeds of approximately $287.5 million. This includes an additional 535,714 shares from the underwriters' full exercise of their option. The offering was conducted under a previously filed shelf registration statement with the SEC. Goldman Sachs & Co. LLC, SVB Leerink LLC, and Cowen and Company, LLC were the joint managers, while Canaccord Genuity LLC served as lead manager.

Positive

• Generated $287.5 million in gross proceeds from the offering.
• Increased financial resources can support business growth and innovation in precision health.

Negative

• Potential share dilution for existing shareholders due to new stock issuance.

Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 4,107,142 shares of its common stock at a public offering price of $70.00 per share, including 535,714 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $287.5 million.

Goldman Sachs & Co. LLC, SVB Leerink LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Canaccord Genuity LLC acted as lead manager for the offering.

The public offering was made pursuant to a shelf registration statement on Form S-3ASR (File No. 333-249925) previously filed with the Securities and Exchange Commission (“SEC”) on November 6, 2020, which automatically became effective upon filing.

The final prospectus supplement and the accompanying prospectus relating to this offering has been filed with the SEC and is available on the SEC’s website located at www.sec.gov, copies of which can be obtained from Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526 or by e-mail at prospectus-ny@ny.email.gs.com, from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by telephone at (800) 808-7525, ext. 6105 or by e-mail at syndicate@svbleerink.com, or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

108019282v.3

View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005803/en/

FAQ

What is the purpose of Quanterix's public offering on February 8, 2023?

The public offering aims to raise capital for advancing precision health through their digital biomarker analysis technology.

How much did Quanterix raise in its recent stock offering?

Quanterix raised approximately $287.5 million in gross proceeds from the offering.

What was the offering price per share in Quanterix's recent public offering?

The shares were offered at a price of $70.00 each.

How many shares of common stock did Quanterix sell in its recent public offering?

Quanterix sold 4,107,142 shares in the public offering.

Who managed the public offering of Quanterix on February 8, 2023?

Goldman Sachs & Co. LLC, SVB Leerink LLC, and Cowen and Company, LLC acted as joint book-running managers.